Published in Virology on March 01, 1994
Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol (1997) 3.23
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J Virol (1995) 3.16
Varicella-zoster virus. Clin Microbiol Rev (1996) 3.03
Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J Virol (1998) 2.71
Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol (1998) 2.34
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol (1997) 1.73
Pseudorabies virus glycoprotein L is necessary for virus infectivity but dispensable for virion localization of glycoprotein H. J Virol (1997) 1.59
The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge. J Virol (1998) 1.57
Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol (1996) 1.49
Expression of herpes simplex virus type 1 glycoprotein L (gL) in transfected mammalian cells: evidence that gL is not independently anchored to cell membranes. J Virol (1995) 1.37
Epstein-Barr virus that lacks glycoprotein gN is impaired in assembly and infection. J Virol (2000) 1.34
Intracellular processing of human herpesvirus 6 glycoproteins Q1 and Q2 into tetrameric complexes expressed on the viral envelope. J Virol (2004) 1.20
Chaperone functions common to nonhomologous Epstein-Barr virus gL and Varicella-Zoster virus gL proteins. J Virol (1997) 1.18
Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex). J Virol (1994) 1.13
The human herpesvirus 6 U100 gene product is the third component of the gH-gL glycoprotein complex on the viral envelope. J Virol (2003) 1.08
Glycoprotein H of herpes simplex virus type 1 requires glycoprotein L for transport to the surfaces of insect cells. J Virol (1997) 1.02
A functional YNKI motif in the short cytoplasmic tail of varicella-zoster virus glycoprotein gH mediates clathrin-dependent and antibody-independent endocytosis. J Virol (2003) 1.02
Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. J Virol (2004) 0.98
Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H. J Virol (2008) 0.81
Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. J Virol (2012) 0.81
Induction of cell-cell fusion from without by human herpesvirus 6B. J Virol (2006) 0.76
The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res (2004) 54.37
The Mouse Genome Database (MGD): integrating biology with the genome. Nucleic Acids Res (2004) 8.91
The Mouse Genome Database (MGD): from genes to mice--a community resource for mouse biology. Nucleic Acids Res (2005) 8.19
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum (2008) 2.71
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Partner's influence on patient preference for treatment in early prostate cancer. BJU Int (2003) 2.33
Role of cytoplasmic vacuoles in varicella-zoster virus glycoprotein trafficking and virion envelopment. J Virol (1988) 2.22
Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect Immun (1978) 2.15
Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail. J Virol (1997) 2.14
Structural analysis of the varicella-zoster virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide moieties. J Virol (1985) 2.09
Primary Epstein-Barr-virus infections in acute neurologic diseases. N Engl J Med (1975) 2.02
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol (1994) 1.99
Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun (1983) 1.95
Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte. J Virol (1995) 1.89
Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol (1992) 1.81
The synthesis of glycoproteins in human melanoma cells infected with varicella-zoster virus. Virology (1980) 1.72
Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. Virology (1995) 1.72
Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics (1981) 1.69
Cell-free varicella-zoster virus in cultured human melanoma cells. J Gen Virol (1979) 1.64
Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor. J Virol (1998) 1.62
Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int (2006) 1.60
New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol (1986) 1.59
Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. J Virol (1993) 1.58
Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J (1990) 1.53
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome. Virology (2001) 1.50
Direct effects of dexamethasone on human podocytes. Kidney Int (2006) 1.50
Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J Virol (1997) 1.50
Site-directed mutagenesis of herpesvirus glycoprotein phosphorylation sites by recombination polymerase chain reaction. PCR Methods Appl (1992) 1.49
Varicella-zoster virus-specific gp140: a highly immunogenic and disulfide-linked structural glycoprotein. Virology (1984) 1.49
Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol (1996) 1.49
Serine protein kinase associated with varicella-zoster virus ORF 47. Virology (1992) 1.48
Pyomyositis in an adolescent female athlete. J Pediatr Surg (1995) 1.43
Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis (1979) 1.40
Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI. J Virol (1993) 1.40
Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology (2006) 1.39
Common expression of varicella-zoster viral glycoprotein antigens in vitro and in chickenpox and zoster vesicles. J Infect Dis (1983) 1.39
Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J Virol (2001) 1.37
Linkage of a gene for dominant non-syndromic deafness to chromosome 19. Hum Mol Genet (1995) 1.36
Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology (1993) 1.36
A stationary-phase protein of Escherichia coli that affects the mode of association between the trp repressor protein and operator-bearing DNA. Proc Natl Acad Sci U S A (1993) 1.35
Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology (1998) 1.35
Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression. J Virol (2001) 1.29
Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology (1990) 1.29
Interactions among structural proteins of varicella zoster virus. Arch Virol Suppl (2001) 1.27
Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII). Virology (1986) 1.23
Phenotypic manifestations of branchio-oto-renal syndrome. Am J Med Genet (1995) 1.23
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis (2007) 1.20
Molecular cloning, characterization, and potential roles of cytosolic and mitochondrial aldehyde dehydrogenases in ethanol metabolism in Saccharomyces cerevisiae. J Bacteriol (1998) 1.18
Chaperone functions common to nonhomologous Epstein-Barr virus gL and Varicella-Zoster virus gL proteins. J Virol (1997) 1.18
Varicella zoster virus glycoprotein gpI is selectively phosphorylated by a virus-induced protein kinase. Proc Natl Acad Sci U S A (1986) 1.18
Bell's palsy and infectious mononucleosis. Lancet (1973) 1.17
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
Response of the μ-opioid system to social rejection and acceptance. Mol Psychiatry (2013) 1.15
Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J Virol (1999) 1.13
Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis (1984) 1.13
Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex). J Virol (1994) 1.13
Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse (2000) 1.09
An autosomal recessive nonsyndromic form of sensorineural hearing loss maps to 3p-DFNB6. Genome Res (1995) 1.09
Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140). J Virol (1987) 1.07
Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers. Neuroscience (2000) 1.06
The immunochemistry of sandwich ELISAs--VI. Greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (CAbs) are denatured by passive adsorption. Mol Immunol (1993) 1.06
The physical and functional behavior of capture antibodies adsorbed on polystyrene. J Immunol Methods (1992) 1.05
Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry (2001) 1.04
Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. J Virol (1985) 1.03
Epstein-Barr virus and Guillain-Barré syndrome. Lancet (1972) 1.03
The potential roles of the conserved amino acids in human liver mitochondrial aldehyde dehydrogenase. J Biol Chem (1997) 1.03
Herpesvirus antibody levels in the etiologic diagnosis of the acute retinal necrosis syndrome. Am J Ophthalmol (1992) 1.02
Cryopreservation of varicella-zoster virions without loss of structural integrity or infectivity. Intervirology (1981) 1.02
Immunoprecipitable polypeptides specified by varicella-zoster virus. Virology (1982) 1.01
Consanguineous nuclear families used to identify a new locus for recessive non-syndromic hearing loss on 14q. Hum Mol Genet (1995) 1.01
ATPase activity of TyrR, a transcriptional regulatory protein for sigma 70 RNA polymerase. J Biol Chem (1993) 1.01
Varicella-zoster virus p32/p36 complex is present in both the viral capsid and the nuclear matrix of the infected cell. J Virol (1986) 1.00
Immunogenic glycoproteins of laboratory and vaccine strains of Varicella-Zoster virus. Infect Immun (1981) 0.99
Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis (1989) 0.98
Molecular cloning, sequencing, and tissue and developmental expression of mouse cartilage oligomeric matrix protein (COMP). J Orthop Res (2000) 0.98
Purification and molecular anatomy of the varicella-zoster virion. Biken J (1983) 0.96
Zoster in children with cancer: radioimmune precipitation profiles of sera before and after illness. J Infect Dis (1983) 0.95
Varicella-zoster viral glycoprotein envelopment: ultrastructural cytochemical localization. J Histochem Cytochem (1986) 0.95
Epitope mapping and tagging by recombination PCR mutagenesis. Biotechniques (1997) 0.95
A gene for autosomal dominant late-onset progressive non-syndromic hearing loss, DFNA10, maps to chromosome 6. Hum Mol Genet (1996) 0.94
Varicella-zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. J Infect Dis (1998) 0.93
DNA polymorphisms in the chicken growth hormone gene: response to selection for disease resistance and association with egg production. Anim Genet (1997) 0.93
Mechanism of selective nonspecific cell-mediated cytotoxicity of virus-infected cells. Nature (1976) 0.92
Primary Epstein-Barr virus infection in a renal transplant recipient. South Med J (1977) 0.92
Glycoprotein gp118 of varicella-zoster virus: purification by serial affinity chromatography. J Virol (1984) 0.91
Immunization of inbred guinea pigs with varicella-zoster virus grown in a syngeneic transformed embryo cell line. J Clin Microbiol (1981) 0.90
DNA mapping of paired varicella-zoster virus isolates from patients with shingles. Lancet (1983) 0.89
Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J (Engl) (1999) 0.89
Interferon-gamma promotes cholinergic differentiation of embryonic septal nuclei and adjacent basal forebrain. Neuron (1994) 0.89
Genomic analysis of varicella-zoster virus: primers for individual open reading frames. J Clin Virol (2003) 0.88
Transformation of primary chick embryo fibroblasts by Marek's disease virus. Virology (1997) 0.88
Optical mapping of BAC clones from the human Y chromosome DAZ locus. Genome Res (2000) 0.87
Pharmacokinetics of 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats. J Pharm Sci (1994) 0.86
Skewed T-cell receptor BV14 and BV16 expression and shared CDR3 sequence and common sequence motifs in synovial T cells of rheumatoid arthritis. Genes Immun (2005) 0.86
Cerebroside antibody titers in antisera capable of myelination inhibition and demyelination. Brain Res (1978) 0.86
Pyomyositis presenting as acute abdominal pain. Pediatr Infect Dis (1984) 0.85
Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not. J Gen Virol (2001) 0.85
Magnetic resonance imaging of the brain in childhood herpesvirus infections. Pediatr Infect Dis J (1987) 0.85